医学
替诺福韦-阿拉芬酰胺
内科学
人口
血压
胃肠病学
替诺福韦
内分泌学
人类免疫缺陷病毒(HIV)
免疫学
病毒载量
环境卫生
抗逆转录病毒疗法
作者
Scott Fung,Calvin Q. Pan,Grace Lai‐Hung Wong,Wai‐Kay Seto,Sang Hoon Ahn,Chi-yi Chen,Hie‐Won Hann,Maciej Jabłkowski,Yoon Jun Kim,Cihan Yurdaydın,Cheng Yuan Peng,Tuan Nguyen,Hiroshi Yatsuhashi,John F. Flaherty,Leland J. Yee,Frida Abramov,Hongyuan Wang,Dzhamal Abdurakhmanov,Young Suk Lim,María Buti
摘要
Patients with chronic hepatitis B (CHB) who switch from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) show changes in lipid profiles.To evaluate how these changes affect cardiovascular risk.This pooled analysis, based on two large prospective studies, evaluated fasting lipid profiles of patients with CHB who were treated with TAF 25 mg/day or TDF 300 mg/day for 96 weeks. Patients who fulfilled the American College of Cardiology criteria (age 40-79 years, high-density lipoprotein [HDL] 20-100 mg/dL, total cholesterol [TC] 130-320 mg/dL and systolic blood pressure 90-200 mmHg) required to assess 10-year atherosclerotic cardiovascular disease (ASCVD) risk with baseline lipid data and at least one post-baseline measurement were included in the ASCVD-risk population. The 10-year ASCVD risk was calculated for patients in this population, and changes from baseline to Week 96 were assessed using intermediate- (≥7.5%) and high-risk (≥20%) cut-offs.Among 1632 patients, 620 (38%) met the criteria for the ASCVD-risk population. At Week 96, fasting levels of all lipids, except TC:HDL ratio, were lower with TDF than TAF. No significant increase was observed in overall ASCVD risk or in any ASCVD-risk categories during the 96-week treatment period compared with baseline. A similar proportion of patients in the TAF and TDF treatment groups (1.3% and 2.3%, respectively; p = 0.34) reported cardiovascular events.Despite on-treatment differences in lipid profiles with TAF and TDF, predicted cardiovascular risk and clinical events were similar for both groups after 96 weeks.
科研通智能强力驱动
Strongly Powered by AbleSci AI